asparagine and ritonavir

asparagine has been researched along with ritonavir in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Blum, LE; Clemente, JC; Dunn, BM; Goodenow, MM; Hemrajani, R	1
Aboulker, JP; Bentata, M; Brun-Vézinet, F; Capitant, C; Chazallon, C; Descamps, D; Katlama, C; Landman, R; Peytavin, G; Pialoux, G; Yéni, P	1

Trials

1 trial(s) available for asparagine and ritonavir

Article	Year
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:1 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asparagine; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphates; Pyridines; Quinolines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load	2009

Article

Year

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:1

Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asparagine; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphates; Pyridines; Quinolines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load

2009

Other Studies

1 other study(ies) available for asparagine and ritonavir

Article	Year
Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. Biochemistry, 2003, Dec-30, Volume: 42, Issue:51 Topics: Alanine; Anti-HIV Agents; Asparagine; Aspartic Acid; Binding Sites; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoleucine; Kinetics; Methionine; Mutagenesis, Site-Directed; Nelfinavir; Ritonavir; Valine	2003

Article

Year

Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.

Biochemistry, 2003, Dec-30, Volume: 42, Issue:51

Topics: Alanine; Anti-HIV Agents; Asparagine; Aspartic Acid; Binding Sites; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoleucine; Kinetics; Methionine; Mutagenesis, Site-Directed; Nelfinavir; Ritonavir; Valine

2003